Tag: CTO PCI


High-Risk Intervention Using the Impella® Pump for Three-Vessel Disease

In this case, Dr. Francis Kim of Hofstra-Northwell School of Medicine in New York presents a patient severely reduced left ventricular systolic function, chronic total occlusion of the right coronary artery (RCA), and prior coronary intervention of the proximal left anterior descending and proximal left circumflex arteries. In addition, the patient had acute anterior wall … Continue reading “High-Risk Intervention Using the Impella® Pump for Three-Vessel Disease”

Mortality Related to Periprocedural Myocardial Injury in CTO-PCI

Key Takeaways

  • Periprocedural myocardial infarction (PMI) is more prevalent in patients undergoing PCI for chronic total occlusions.
  • Patients with PMI who require multiple lesion treatment, a retrograde approach to therapy, and more stents had a higher rate of mortality at follow-up.
Risks to the myocardium during percutaneous coronary intervention (PCI) have been minimized over the last few decades due to the advancement of interventional cardiology techniques and technology. Adverse events (AEs) following PCI are not uncommon, however, despite the ability of PCI to improve life quality among patients with coronary artery disease. Periprocedural myocardial injury (PMI) is one such AE that can occur during PCI and can be detected in up to 80% of patients. Continue readingMortality Related to Periprocedural Myocardial Injury in CTO-PCI

CTO Impact on the Long-Term Prognosis of Ischemic Systolic Heart Failure

Key Takeaways

  • Previous studies indicate the presence of chronic total occlusion (CTO) in hospitalized acute coronary syndrome patients correlates with higher incidences of in-hospital and long-term mortality.
  • This study shows that presence of CTO in coronary artery disease (CAD) patients with ischemic heart failure results in adverse long-term prognosis.
In 2016, the recorded prevalence of heart failure (HF) in the United States was 5.7 million, with an estimated 670,000 new diagnoses each year.1 The rates of post-discharge mortality and readmissions following treatment for HF have remained unchanged, despite the improvement in outcomes of ambulatory HF patents.2 Continue readingCTO Impact on the Long-Term Prognosis of Ischemic Systolic Heart Failure